Filtered By:
Source: Current Issues in Molecular Biology
Therapy: Cancer Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 213 results found since Jan 2013.
Repurposing of the Drug Tezosentan for Cancer Therapy
Curr Issues Mol Biol. 2023 Jun 11;45(6):5118-5131. doi: 10.3390/cimb45060325.ABSTRACTTezosentan is a vasodilator drug that was originally developed to treat pulmonary arterial hypertension. It acts by inhibiting endothelin (ET) receptors, which are overexpressed in many types of cancer cells. Endothelin-1 (ET1) is a substance produced by the body that causes blood vessels to narrow. Tezosentan has affinity for both ETA and ETB receptors. By blocking the effects of ET1, tezosentan can help to dilate blood vessels, improve the blood flow, and reduce the workload on the heart. Tezosentan has been found to have anticancer prop...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Eduarda Ribeiro Nuno Vale Source Type: research
Synergistic Effects of New Curcumin Analog (PAC) and Cisplatin on Oral Cancer Therapy
In this study, we aimed to assess the potential complementary effects of PAC in combination with cisplatin for treating oral cancer. We conducted experiments using oral cancer cell lines (Ca9-22) treated with different concentrations of cisplatin (ranging from 0.1 μM to 1 μM), either alone or in conjunction with PAC (2.5 and 5 μM). Cell growth was measured using the MTT assay, while cell cytotoxicity was evaluated using an LDH assay. Propidium iodide and annexin V staining were employed to examine the impact on cell apoptosis. Flow cytometry was used to investigate the effects of the PAC/cisplatin combination on cancer ...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Abdelhabib Semlali Sarra Beji Ikram Ajala Mohammed Al-Zharani Mahmoud Rouabhia Source Type: research
Repurposing of the Drug Tezosentan for Cancer Therapy
Curr Issues Mol Biol. 2023 Jun 11;45(6):5118-5131. doi: 10.3390/cimb45060325.ABSTRACTTezosentan is a vasodilator drug that was originally developed to treat pulmonary arterial hypertension. It acts by inhibiting endothelin (ET) receptors, which are overexpressed in many types of cancer cells. Endothelin-1 (ET1) is a substance produced by the body that causes blood vessels to narrow. Tezosentan has affinity for both ETA and ETB receptors. By blocking the effects of ET1, tezosentan can help to dilate blood vessels, improve the blood flow, and reduce the workload on the heart. Tezosentan has been found to have anticancer prop...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Eduarda Ribeiro Nuno Vale Source Type: research
Synergistic Effects of New Curcumin Analog (PAC) and Cisplatin on Oral Cancer Therapy
In this study, we aimed to assess the potential complementary effects of PAC in combination with cisplatin for treating oral cancer. We conducted experiments using oral cancer cell lines (Ca9-22) treated with different concentrations of cisplatin (ranging from 0.1 μM to 1 μM), either alone or in conjunction with PAC (2.5 and 5 μM). Cell growth was measured using the MTT assay, while cell cytotoxicity was evaluated using an LDH assay. Propidium iodide and annexin V staining were employed to examine the impact on cell apoptosis. Flow cytometry was used to investigate the effects of the PAC/cisplatin combination on cancer ...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Abdelhabib Semlali Sarra Beji Ikram Ajala Mohammed Al-Zharani Mahmoud Rouabhia Source Type: research
Metabolic Silencing via Methionine-Based Amino Acid Restriction in Head and Neck Cancer
Curr Issues Mol Biol. 2023 May 24;45(6):4557-4573. doi: 10.3390/cimb45060289.ABSTRACTIn recent years, various forms of caloric restriction (CR) and amino acid or protein restriction (AAR or PR) have shown not only success in preventing age-associated diseases, such as type II diabetes and cardiovascular diseases, but also potential for cancer therapy. These strategies not only reprogram metabolism to low-energy metabolism (LEM), which is disadvantageous for neoplastic cells, but also significantly inhibit proliferation. Head and neck squamous cell carcinoma (HNSCC) is one of the most common tumour types, with over 600,000 ...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Anna Chiara W ünsch Elena Ries Sina Heinzelmann Andrea Frabschka Peter Christoph Wagner Theresa Rauch Corinna Koderer Mohamed El-Mesery Julian Manuel Volland Alexander Christian K übler Stefan Hartmann Axel Seher Source Type: research
Repurposing of the Drug Tezosentan for Cancer Therapy
Curr Issues Mol Biol. 2023 Jun 11;45(6):5118-5131. doi: 10.3390/cimb45060325.ABSTRACTTezosentan is a vasodilator drug that was originally developed to treat pulmonary arterial hypertension. It acts by inhibiting endothelin (ET) receptors, which are overexpressed in many types of cancer cells. Endothelin-1 (ET1) is a substance produced by the body that causes blood vessels to narrow. Tezosentan has affinity for both ETA and ETB receptors. By blocking the effects of ET1, tezosentan can help to dilate blood vessels, improve the blood flow, and reduce the workload on the heart. Tezosentan has been found to have anticancer prop...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Eduarda Ribeiro Nuno Vale Source Type: research
Synergistic Effects of New Curcumin Analog (PAC) and Cisplatin on Oral Cancer Therapy
In this study, we aimed to assess the potential complementary effects of PAC in combination with cisplatin for treating oral cancer. We conducted experiments using oral cancer cell lines (Ca9-22) treated with different concentrations of cisplatin (ranging from 0.1 μM to 1 μM), either alone or in conjunction with PAC (2.5 and 5 μM). Cell growth was measured using the MTT assay, while cell cytotoxicity was evaluated using an LDH assay. Propidium iodide and annexin V staining were employed to examine the impact on cell apoptosis. Flow cytometry was used to investigate the effects of the PAC/cisplatin combination on cancer ...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Abdelhabib Semlali Sarra Beji Ikram Ajala Mohammed Al-Zharani Mahmoud Rouabhia Source Type: research
Metabolic Silencing via Methionine-Based Amino Acid Restriction in Head and Neck Cancer
Curr Issues Mol Biol. 2023 May 24;45(6):4557-4573. doi: 10.3390/cimb45060289.ABSTRACTIn recent years, various forms of caloric restriction (CR) and amino acid or protein restriction (AAR or PR) have shown not only success in preventing age-associated diseases, such as type II diabetes and cardiovascular diseases, but also potential for cancer therapy. These strategies not only reprogram metabolism to low-energy metabolism (LEM), which is disadvantageous for neoplastic cells, but also significantly inhibit proliferation. Head and neck squamous cell carcinoma (HNSCC) is one of the most common tumour types, with over 600,000 ...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Anna Chiara W ünsch Elena Ries Sina Heinzelmann Andrea Frabschka Peter Christoph Wagner Theresa Rauch Corinna Koderer Mohamed El-Mesery Julian Manuel Volland Alexander Christian K übler Stefan Hartmann Axel Seher Source Type: research
Repurposing of the Drug Tezosentan for Cancer Therapy
Curr Issues Mol Biol. 2023 Jun 11;45(6):5118-5131. doi: 10.3390/cimb45060325.ABSTRACTTezosentan is a vasodilator drug that was originally developed to treat pulmonary arterial hypertension. It acts by inhibiting endothelin (ET) receptors, which are overexpressed in many types of cancer cells. Endothelin-1 (ET1) is a substance produced by the body that causes blood vessels to narrow. Tezosentan has affinity for both ETA and ETB receptors. By blocking the effects of ET1, tezosentan can help to dilate blood vessels, improve the blood flow, and reduce the workload on the heart. Tezosentan has been found to have anticancer prop...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Eduarda Ribeiro Nuno Vale Source Type: research
Synergistic Effects of New Curcumin Analog (PAC) and Cisplatin on Oral Cancer Therapy
In this study, we aimed to assess the potential complementary effects of PAC in combination with cisplatin for treating oral cancer. We conducted experiments using oral cancer cell lines (Ca9-22) treated with different concentrations of cisplatin (ranging from 0.1 μM to 1 μM), either alone or in conjunction with PAC (2.5 and 5 μM). Cell growth was measured using the MTT assay, while cell cytotoxicity was evaluated using an LDH assay. Propidium iodide and annexin V staining were employed to examine the impact on cell apoptosis. Flow cytometry was used to investigate the effects of the PAC/cisplatin combination on cancer ...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Abdelhabib Semlali Sarra Beji Ikram Ajala Mohammed Al-Zharani Mahmoud Rouabhia Source Type: research
Metabolic Silencing via Methionine-Based Amino Acid Restriction in Head and Neck Cancer
Curr Issues Mol Biol. 2023 May 24;45(6):4557-4573. doi: 10.3390/cimb45060289.ABSTRACTIn recent years, various forms of caloric restriction (CR) and amino acid or protein restriction (AAR or PR) have shown not only success in preventing age-associated diseases, such as type II diabetes and cardiovascular diseases, but also potential for cancer therapy. These strategies not only reprogram metabolism to low-energy metabolism (LEM), which is disadvantageous for neoplastic cells, but also significantly inhibit proliferation. Head and neck squamous cell carcinoma (HNSCC) is one of the most common tumour types, with over 600,000 ...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Anna Chiara W ünsch Elena Ries Sina Heinzelmann Andrea Frabschka Peter Christoph Wagner Theresa Rauch Corinna Koderer Mohamed El-Mesery Julian Manuel Volland Alexander Christian K übler Stefan Hartmann Axel Seher Source Type: research
